secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-05-12T21:07:04+00:00
Accession:  0001193125-26-219801
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy
--------------------------------------------------------------------------------

- Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.
- Cash, equivalents and marketable securities $388.9M as of March 31, 2026; runway into 2028.
- BBO-8520 monotherapy ORR 65% in KRAS G12C NSCLC; BBO-11818 partial response in pancreatic cancer.
- BBO-10203 achieved target engagement with no hyperglycemia; clinical benefit in CRC and HR+ BC.
- Pedro Beltran appointed CEO, Idan Elmelech COO effective April 20, 2026; Neil Kumar Executive Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/0001193125-26-219801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/bbot-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer